HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cognis certified natural

This article was originally published in The Rose Sheet

Executive Summary

Raw materials supplier Cognis says 30 of its cosmetic oils, emulsifiers and surfactants have been certified for use in natural personal-care products by BDIH (Association of German Industries and Trading Firms). Noting the booming demand for "green" personal care, Cognis says that "up until now, manufacturers of cosmetics and personal hygiene products who wanted their end products to be awarded [BDIH's] official seal had to ask Cognis to fill out a lengthy form with details about the raw materials used. But now that Cognis has obtained certification for its ingredients, it is much simpler for [its] Care Chemicals customers to formulate natural cosmetics that comply with the BDIH guidelines." More than 130 companies - including 25 outside of Germany - market products that bear BDIH's stamp of approval, according to Cognis, which maintains the seal gives companies "a clear competitive advantage," especially in German-speaking markets. Other Cognis offerings currently are being evaluated for BDIH certification, firm notes. Ninety Cognis ingredients are "green" by Ecocert standards, it adds...

You may also be interested in...



Can Organovo Leverage Its Solid Phase II Data In MASH?

Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.

Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune

The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.

Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel

Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015522

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel